Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-07 |
2024-09 |
-0.1 |
N/A |
N/A |
N/A |
2024-08-08 |
2024-06 |
0.03 |
-0.09 |
-0.12 |
-400.00% |
2024-05-13 |
2024-03 |
-0.16 |
-0.14 |
0.02 |
12.50% |
2024-03-14 |
2023-12 |
-0.15 |
-0.12 |
0.03 |
20.00% |
2023-11-02 |
2023-09 |
-0.18 |
-0.11 |
0.07 |
38.89% |
2023-08-03 |
2023-06 |
-0.19 |
-0.16 |
0.03 |
15.79% |
Date |
Firm |
Action |
From |
To |
2023-09-06 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2023-08-06 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2022-12-18 |
B. Riley Securities |
Upgrade |
|
Neutral |
2022-09-01 |
Cantor Fitzgerald |
Upgrade |
|
Overweight |
2022-05-18 |
B. Riley Securities |
Upgrade |
|
Neutral |
2021-11-01 |
Cantor Fitzgerald |
Upgrade |
|
Overweight |
Date |
Name |
Relation |
Quantity |
Description |
2024-03-17 |
BERG EDWARD B |
General Counsel |
270.71K |
Stock Award(Grant) |
2024-03-17 |
CUMMINGS JAMES F. |
Officer |
330.09K |
Stock Award(Grant) |
2024-06-10 |
FINNEY MICHAEL J |
Director |
686.84K |
Stock Award(Grant) |
2024-06-10 |
HERON ELAINE J |
Director |
40.57K |
Stock Award(Grant) |
2024-03-17 |
LEE PHILLIP E. |
Chief Financial Officer |
241.81K |
Stock Award(Grant) |
2024-03-17 |
LO STEVEN |
Chief Executive Officer |
250.00K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Cantor Fitzgerald, L. P. |
7.09M |
5.17M |
4.66% |
2023-06-29 |
Vanguard Group Inc |
6.89M |
5.03M |
4.54% |
2023-06-29 |
Millennium Management Llc |
2.14M |
1.56M |
1.41% |
2023-06-29 |
Blackrock Inc. |
1.93M |
1.41M |
1.27% |
2023-06-29 |
Geode Capital Management, LLC |
1.57M |
1.15M |
1.03% |
2023-06-29 |
Renaissance Technologies, LLC |
792.01K |
578.16K |
0.52% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
4.07M |
2.97M |
2.68% |
2023-06-29 |
Vanguard Extended Market Index Fund |
1.77M |
1.29M |
1.16% |
2023-05-30 |
Fidelity Extended Market Index Fund |
631.59K |
770.54K |
0.42% |
2023-05-30 |
Schwab Strategic Tr-Schwab U.S. Small Cap ETF |
559.90K |
683.08K |
0.37% |
2023-05-30 |
Vanguard Health Care Index Fund |
480.63K |
586.37K |
0.32% |
2023-06-29 |
Vanguard Horizon Fund-Strategic Small-Cap Equity Fund |
361.97K |
264.24K |
0.24% |
Dividend |
Date |
0.1847 |
2012-11-09 |
Split |
Date |
1 : 11 |
2018-02-14 |
0.16667 : 1 |
2012-11-09 |